You are here

  • Home
  • Archive
  • Volume 9, Issue 2
  • Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors

 

Online download statistics by month:

Online download statistics by month: February 2021 to September 2025

AbstractFullPdf
Feb 2021686686284
Mar 2021383383124
Apr 2021199199104
May 202117917992
Jun 2021260260129
Jul 2021179179108
Aug 202117117185
Sep 2021154154107
Oct 202114114183
Nov 202116416383
Dec 202113413445
Jan 202214215261
Feb 202211512066
Mar 2022213220125
Apr 202214214568
May 202211711774
Jun 202212813264
Jul 202212413869
Aug 202215416049
Sep 202212612953
Oct 202214114346
Nov 202213413446
Dec 202212913045
Jan 202312412753
Feb 202316416460
Mar 202316716866
Apr 202311111335
May 202314114238
Jun 202313914128
Jul 2023929232
Aug 2023969740
Sep 2023989936
Oct 202313013022
Nov 202320220235
Dec 202320320325
Jan 2024747634
Feb 2024696937
Mar 2024979741
Apr 202413713877
May 202410410548
Jun 2024939553
Jul 2024949633
Aug 2024939438
Sep 2024878753
Oct 2024888944
Nov 202413313483
Dec 202415215886
Jan 202510210242
Feb 202510210239
Mar 202512512539
Apr 202514814961
May 202514714877
Jun 202510510540
Jul 2025110
Sep 2025110
Total793480183405